Monoparamunity inducers based on attenuated rabbit myxomaviruses

Abstract

The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.

1 - 48 . (canceled) 
     
     
         49 . An attenuated myxomavirus generated by a method comprising the steps of:
 isolating a myxomavirus from infected tissue of a rabbit;   adapting the virus to a permissive cell system;   passaging the adapted virus in a cell culture; and   selecting an attenuated myxomavirus that induces paramunity.   
     
     
         50 . The attenuated myxomavirus of  claim 49 , wherein the adaptation of the virus to a permissive cell system comprises culturing the virus on a chorioallantoic membrane of an incubated chicken egg. 
     
     
         51 . The attenuated myxomavirus of  claim 49 , wherein the passaging the adapted virus in a cell culture comprises:
 passaging the adapted virus in Vero monkey kidney cells;   passaging the Vero cell passaged virus in a binary cell culture obtained by cell fusion between chicken embryo fibroblast cells and Vero monkey kidney cells; and   passaging the binary cell passaged virus in Vero monkey kidney cells.   
     
     
         52 . The attenuated myxomavirus of  claim 49 , wherein the myxomavirus has lost the receptor properties of one or more myxomavirus interferon receptor, one or more myxomavirus tumor necrosis factor receptor, and one or more myxomavirus interleukin receptor. 
     
     
         53 . The attenuated myxomavirus of  claim 49 , wherein the attenuated myxomavirus has lost the receptor properties of the myxomavirus cytokine receptors IFNα-R, IFNγ-R, TNF-R, IL-1-R, IL-2-R, IL-6-R, and IL-12-R. 
     
     
         54 . The attenuated myxomavirus of  claim 49 , wherein the attenuated myxomavirus is inactivated with beta-propiolactone. 
     
     
         55 . The attenuated myxomavirus of  claim 54 , wherein the beta-propiolactone is at a concentration of 0.01%-1%. 
     
     
         56 . A pharmaceutical composition comprising the attenuated myxomavirus of  claim 49 . 
     
     
         57 . A pharmaceutical composition comprising the attenuated myxomavirus of  claim 50 . 
     
     
         58 . A pharmaceutical composition comprising the attenuated myxomavirus of  claim 51 . 
     
     
         59 . A pharmaceutical composition comprising the attenuated myxomavirus of  claim 52 . 
     
     
         60 . A pharmaceutical composition comprising the attenuated myxomavirus of  claim 53 . 
     
     
         61 . A pharmaceutical composition comprising the attenuated myxomavirus of  claim 54 . 
     
     
         62 . The pharmaceutical composition of  claim 56 , wherein the pharmaceutical composition comprises at least 10 6.5  TCID 50  of the attenuated myxomavirus. 
     
     
         63 . The pharmaceutical composition of  claim 57 , wherein the pharmaceutical composition comprises at least 10 6.5  TCID 50  of the attenuated myxomavirus. 
     
     
         64 . The pharmaceutical composition of  claim 58 , wherein the pharmaceutical composition comprises at least 10 6.5  TCID 50  of the attenuated myxomavirus. 
     
     
         65 . The pharmaceutical composition of  claim 59 , wherein the pharmaceutical composition comprises at least 10 6.5  TCID 50  of the attenuated myxomavirus. 
     
     
         66 . The pharmaceutical composition of  claim 60 , wherein the pharmaceutical composition comprises at least 10 6.5  TCID 50  of the attenuated myxomavirus. 
     
     
         67 . The pharmaceutical composition of  claim 61 , wherein the pharmaceutical composition comprises at least 10 6.5  TCID 50  of the attenuated myxomavirus.